A detailed history of Pro Share Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Pro Share Advisors LLC holds 316,396 shares of BMY stock, worth $18.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
316,396
Previous 338,422 6.51%
Holding current value
$18.3 Million
Previous $14.1 Million 16.5%
% of portfolio
0.04%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $873,551 - $1.14 Million
-22,026 Reduced 6.51%
316,396 $16.4 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $1.06 Million - $1.39 Million
26,267 Added 8.41%
338,422 $14.1 Million
Q1 2024

May 08, 2024

SELL
$47.98 - $54.4 $361,289 - $409,632
-7,530 Reduced 2.36%
312,155 $16.9 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $181,606 - $216,706
-3,746 Reduced 1.16%
319,685 $16.4 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $936,833 - $1.05 Million
-16,183 Reduced 4.77%
323,431 $18.8 Million
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $260,828 - $289,609
4,094 Added 1.22%
339,614 $21.7 Million
Q1 2023

May 11, 2023

BUY
$65.71 - $74.53 $2.8 Million - $3.18 Million
42,655 Added 14.56%
335,520 $23.3 Million
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $133,878 - $158,530
-1,955 Reduced 0.66%
292,865 $21.1 Million
Q3 2022

Nov 04, 2022

SELL
$0.13 - $76.84 $4,154 - $2.46 Million
-31,955 Reduced 9.78%
294,820 $21 Million
Q2 2022

Aug 01, 2022

SELL
$72.62 - $79.98 $9.92 Million - $10.9 Million
-136,568 Reduced 29.47%
326,775 $25.2 Million
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $1.19 Million - $1.42 Million
-19,328 Reduced 4.0%
463,343 $33.8 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $3.8 Million - $4.43 Million
70,786 Added 17.19%
482,671 $30.1 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $653,946 - $766,014
-11,052 Reduced 2.61%
411,885 $24.4 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $3.69 Million - $4.02 Million
59,611 Added 16.41%
422,937 $28.3 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $750,057 - $843,593
12,640 Added 3.6%
363,326 $22.9 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $1.66 Million - $1.89 Million
28,827 Added 8.96%
350,686 $21.8 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $279,856 - $310,117
4,873 Added 1.54%
321,859 $19.4 Million
Q2 2020

Aug 03, 2020

BUY
$54.82 - $64.09 $1.16 Million - $1.36 Million
21,216 Added 7.17%
316,986 $18.6 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $7.71 Million - $11.2 Million
-166,060 Reduced 35.96%
295,770 $16.5 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $9.1 Million - $11.9 Million
184,983 Added 66.82%
461,830 $29.6 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $933,711 - $1.11 Million
21,831 Added 8.56%
276,847 $14 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $1.3 Million - $1.44 Million
-29,203 Reduced 10.27%
255,016 $11.6 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $553,848 - $660,395
12,275 Added 4.51%
284,219 $13.6 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $640,852 - $831,031
13,143 Added 5.08%
271,944 $14.1 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $1.15 Million - $1.3 Million
-20,884 Reduced 7.47%
258,801 $16.1 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $843,800 - $1.05 Million
-16,699 Reduced 5.63%
279,685 $15.5 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $1.39 Million - $1.6 Million
-23,154 Reduced 7.25%
296,384 $18.7 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $4.31 Million - $4.7 Million
71,944 Added 29.06%
319,538 $19.6 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $803,154 - $926,907
14,542 Added 6.24%
247,594 $15.8 Million
Q2 2017

Aug 11, 2017

BUY
N/A
233,052
233,052 $13 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.